Key Takeaways; Cannabis Sector • The Cannabist Company celebrated approval for adult-use cannabis sales in New York. • Curaleaf gained conditional approval for uplisting to the Toronto Stock Exchange. • MedMen prevailed in legal battle against Whitestar Solutions allegations. Key Takeaways; Psychedelic Sector • Awakn received regulatory and ethical approval for Phase III clinical trial […]
Filament Health and PharmAla Biotech also completed shipments to a number of Australian clientsVANCOUVER, British Columbia, Nov. 15, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”) (CSE:MDMA)(OTCQB:PMBHF), a Canadian biotechnology company dedicated to the research and development of clinical-grade LaNeo™ MDMA and novel MDXX compounds, and Filament Health Corp. (OTCQB:FLHLF) (NEO:FH) (FSE:7QS) (“Filament”), a clinical-stage natural psychedelic drug development company, today